Start here if you're new
what it is
SSII builds and sells surgical robots, then makes money from the tools and service that keep them running.
how it gets paid
Last year Ss Innovations Intl made $42M in revenue.
why it's growing
Revenue grew 105.7% last year. That quarter alone equaled about 66.7% of the full $42M trailing annual revenue base.
what just happened
Revenue hit $28M, up 118% vs. prior year, but EPS stayed negative at -$0.05.
At a glance
n/a balance sheet
$2B fy2026 rev est
19.3% operating margin
~$867M market cap
small cap
What they do
SSII builds and sells surgical robots, then makes money from the tools and service that keep them running.
As of December 31, 2024, SSII had 62 systems installed, and 58 were in India. Installed base -> robots already placed in hospitals -> your surgeons, nurses, and staff get trained on one system -> replacing it gets harder and follow-on sales get easier. The quiet part is simple: 62 machines is tiny next to global medtech giants, but it is still a real footprint in a market where zero installed systems gets you nowhere.
How they make money
$42M
annual revenue · their business grew +105.7% last year
total revenue
$42M
+105.7%
The products that matter
robot-assisted surgery platform
SSi Mantra
$42M · 100% of revenue
this is the whole business today. SSi Mantra drives 100% of the company's $42M in annual revenue, so product traction and company traction are the same sentence.
single platform
Key numbers
$42M
annual revenue
Revenue hit $42M, up 105.7% vs. prior year. Fast growth is real. The business is just still small against an $867M market cap.
19.3%
operating margin
Operating margin -> money left after running the business -> SSII still loses about 19 cents on every sales dollar, so scale has not fixed the cost base yet.
$2M
long-term debt
Long-term debt is just $2M, or 0% of capital. The balance sheet is light on leverage, so your main risk is execution, not creditors.
62
systems installed
Installed systems reached 62 by December 31, 2024. In medical devices, placed machines are the start of future tool and service revenue.
Financial health
n/a
strength
- balance sheet grade n/a
- long-term debt $2M (0% of capital)
n/a — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for SSII right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue hit $28M, up 118% vs. prior year, but EPS stayed negative at -$0.05.
That quarter alone equaled about 66.7% of the full $42M trailing annual revenue base. Gross margin was 47.1%, which says product economics look better than the bottom line.
$28M
revenue
-$0.05
eps
47.1%
gross margin
the number that mattered
Gross margin of 47.1% is the tell. Gross margin -> money left after making the product -> so the robot can earn decent hardware economics even while total operating costs still run too high.
source: company earnings report, 2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is valuation outrunning adoption of the SSi Mantra platform.
med
single-product concentration
SSi Mantra accounts for 100% of revenue. If the platform hits a technical issue, adoption problem, or reimbursement hurdle, there is no second engine to keep the business moving.
100% of the current $42M revenue base sits behind one product line.
med
valuation ahead of proof
An $867M market cap on $42M of revenue is about 20.6x sales. That multiple assumes a lot of future success is already spoken for.
If growth cools, the stock can fall even if the company still grows in absolute terms.
med
competition against established surgical robotics players
The company is going after a market where Intuitive Surgical's da Vinci is the reference point. Early positioning in India helps, but it does not erase the challenge of competing against an entrenched category leader.
Pricing pressure, slower adoption, or weaker surgeon preference would directly slow the path from $42M toward the numbers embedded in the valuation.
med
thin coverage and limited outside verification
This page already shows the issue: no composite score, no balance sheet grade, and limited analyst and ownership data. When coverage is thin, investors depend more heavily on management disclosure and execution.
The risk is not only what the company does. It is how little independent signal you have while it does it.
With 100% of $42M revenue tied to one platform and the stock valued at about 20.6x sales, SSII does not need a collapse to rerate lower. It only needs adoption to run slower than the multiple assumes.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
annual general meeting on 23 feb 2026
This is the next formal corporate checkpoint. For a thinly covered company, scheduled governance events matter more because there are fewer outside voices filling the gap.
growth
whether revenue can stay near its current triple-digit pace
+105.7% growth looks great. The harder part is doing anything close to that again at larger scale with the stock already priced for a much bigger business.
valuation gap
the distance between $42M today and the $2B fy2026 estimate
That gap is the whole debate. Each reporting cycle that does not narrow it puts more pressure on the multiple than on the story.
milestone
management's 01/06/2026 pediatric and cardiac expansion target
This is one of the few dated operating milestones disclosed on the page. If it advances cleanly, the one-platform story gets broader. If it slips, the valuation has less to lean on.
Analyst rankings
source: institutional data
Institutional activity
institutional ownership data for SSII is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$5
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive